Dan Brennan
Stock Analyst at TD Securities
(3.91)
# 589
Out of 4,893 analysts
107
Total ratings
48.84%
Success rate
11.17%
Average return
Main Sectors:
Stocks Rated by Dan Brennan
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
GH Guardant Health | Maintains: Buy | $56 → $60 | $51.04 | +17.55% | 2 | May 1, 2025 | |
WGS GeneDx Holdings | Maintains: Buy | $135 → $110 | $91.88 | +19.72% | 4 | May 1, 2025 | |
MRVI Maravai LifeSciences Holdings | Maintains: Neutral | $8 → $2.5 | $2.76 | -9.42% | 4 | Mar 21, 2025 | |
TEM Tempus AI | Reinstates: Buy | $74 | $58.41 | +26.69% | 2 | Feb 5, 2025 | |
EXAS Exact Sciences | Maintains: Buy | $82 → $86 | $55.31 | +55.49% | 6 | Nov 26, 2024 | |
NTRA Natera | Maintains: Buy | $155 → $175 | $161.75 | +8.19% | 4 | Nov 13, 2024 | |
CRL Charles River Laboratories International | Maintains: Buy | $240 → $250 | $158.97 | +57.26% | 5 | Nov 7, 2024 | |
BRKR Bruker | Maintains: Hold | $72 → $70 | $42.12 | +66.19% | 1 | Nov 6, 2024 | |
ILMN Illumina | Maintains: Buy | $166 → $177 | $97.44 | +81.65% | 12 | Nov 5, 2024 | |
RVTY Revvity | Maintains: Buy | $141 → $144 | $100.13 | +43.81% | 3 | Nov 5, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $363 → $410 | $349.21 | +17.41% | 3 | Nov 4, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $310 → $315 | $200.96 | +56.75% | 5 | Oct 23, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $153 → $160 | $121.30 | +31.90% | 12 | Aug 22, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $28 → $30 | $5.72 | +424.48% | 1 | Aug 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $31 | $13.57 | +128.45% | 3 | Jul 29, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $648 → $658 | $419.88 | +56.71% | 12 | Jul 25, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $51 | $42.61 | +19.69% | 2 | Jul 23, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2.8 | $0.32 | +785.80% | 1 | May 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $7.53 | +165.60% | 6 | May 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $57 → $32 | $12.10 | +164.46% | 4 | May 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $545 → $546 | $235.89 | +131.46% | 4 | Dec 8, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $2.20 | +218.18% | 1 | May 31, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $13 → $15 | $1.48 | +913.51% | 1 | Mar 31, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $207 → $232 | $150.53 | +54.12% | 6 | Mar 1, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $770 → $880 | $1,218.65 | -27.79% | 3 | Oct 7, 2020 |
Guardant Health
May 1, 2025
Maintains: Buy
Price Target: $56 → $60
Current: $51.04
Upside: +17.55%
GeneDx Holdings
May 1, 2025
Maintains: Buy
Price Target: $135 → $110
Current: $91.88
Upside: +19.72%
Maravai LifeSciences Holdings
Mar 21, 2025
Maintains: Neutral
Price Target: $8 → $2.5
Current: $2.76
Upside: -9.42%
Tempus AI
Feb 5, 2025
Reinstates: Buy
Price Target: $74
Current: $58.41
Upside: +26.69%
Exact Sciences
Nov 26, 2024
Maintains: Buy
Price Target: $82 → $86
Current: $55.31
Upside: +55.49%
Natera
Nov 13, 2024
Maintains: Buy
Price Target: $155 → $175
Current: $161.75
Upside: +8.19%
Charles River Laboratories International
Nov 7, 2024
Maintains: Buy
Price Target: $240 → $250
Current: $158.97
Upside: +57.26%
Bruker
Nov 6, 2024
Maintains: Hold
Price Target: $72 → $70
Current: $42.12
Upside: +66.19%
Illumina
Nov 5, 2024
Maintains: Buy
Price Target: $166 → $177
Current: $97.44
Upside: +81.65%
Revvity
Nov 5, 2024
Maintains: Buy
Price Target: $141 → $144
Current: $100.13
Upside: +43.81%
Nov 4, 2024
Maintains: Hold
Price Target: $363 → $410
Current: $349.21
Upside: +17.41%
Oct 23, 2024
Maintains: Buy
Price Target: $310 → $315
Current: $200.96
Upside: +56.75%
Aug 22, 2024
Maintains: Buy
Price Target: $153 → $160
Current: $121.30
Upside: +31.90%
Aug 7, 2024
Maintains: Hold
Price Target: $28 → $30
Current: $5.72
Upside: +424.48%
Jul 29, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $13.57
Upside: +128.45%
Jul 25, 2024
Maintains: Buy
Price Target: $648 → $658
Current: $419.88
Upside: +56.71%
Jul 23, 2024
Maintains: Buy
Price Target: $48 → $51
Current: $42.61
Upside: +19.69%
May 13, 2024
Initiates: Buy
Price Target: $2.8
Current: $0.32
Upside: +785.80%
May 1, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $7.53
Upside: +165.60%
May 1, 2024
Downgrades: Hold
Price Target: $57 → $32
Current: $12.10
Upside: +164.46%
Dec 8, 2023
Maintains: Outperform
Price Target: $545 → $546
Current: $235.89
Upside: +131.46%
May 31, 2023
Initiates: Outperform
Price Target: $7
Current: $2.20
Upside: +218.18%
Mar 31, 2023
Upgrades: Outperform
Price Target: $13 → $15
Current: $1.48
Upside: +913.51%
Mar 1, 2021
Upgrades: Buy
Price Target: $207 → $232
Current: $150.53
Upside: +54.12%
Oct 7, 2020
Downgrades: Sell
Price Target: $770 → $880
Current: $1,218.65
Upside: -27.79%